Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer

@article{Shiota2014RiskFF,
  title={Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer},
  author={Masaki Shiota and Akira Yokomizo and Ario Takeuchi and Keijiro Kiyoshima and Junichi Inokuchi and Katsunori Tatsugami and Seiji Naito},
  journal={Supportive Care in Cancer},
  year={2014},
  volume={22},
  pages={3219-3226}
}
Docetaxel is a standard therapy for patients with castration-resistant prostate cancer (CRPC). However, docetaxel-associated adverse events (AEs) such as febrile neutropenia (FN) can impair quality of life and may become life-threatening. In this study, we clarified the AEs and risk factors associated with FN in clinical settings. This study included 37 Japanese patients with CRPC who were treated with 70–75 mg/m2 docetaxel and 10 mg prednisone every 3 or 4 weeks between 2008 and 2012. AEs… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 40 references

a prospective study

O Arrieta, RM Michel Ortega, +7 authors chemotherapy serum albumin levels with development of toxicity paclitaxelcisplatin
BMC Cancer 10:50 Support Care Cancer • 2014
View 1 Excerpt

patients

CL Bennett, B Djulbegovic, LB Norris, JO Armitage
2013

Similar Papers

Loading similar papers…